Design and synthesis of novel α1a adrenoceptor-selective antagonists.: 1.: Structure-activity relationship in dihydropyrimidinones

被引:134
作者
Nagarathnam, D
Miao, SW
Lagu, B
Chiu, G
Fang, J
Dhar, TGM
Zhang, J
Tyagarajan, S
Marzabadi, MR
Zhang, FQ
Wong, WC
Sun, WY
Tian, D
Wetzel, JM
Forray, C
Chang, RSL
Broten, TP
Ransom, RW
Schorn, TW
Chen, TB
O'Malley, S
Kling, P
Schneck, K
Bendesky, R
Harrell, CM
Vyas, KP
Gluchowski, C
机构
[1] Synapt Pharmaceut Corp, Dept Chem, Paramus, NJ USA
[2] Synapt Pharmaceut Corp, Dept Pharmacol, Paramus, NJ 07652 USA
[3] Merck Sharp & Dohme Ltd, Dept Pharmacol, West Point, PA 19486 USA
[4] Merck Sharp & Dohme Ltd, Dept Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.1021/jm990200p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dihydropyrimidinones such as compound 12 exhibited high binding affinity and subtype selectivity for the cloned human alpha(1a) receptor. Systematic modifications of 12 led to identification of highly potent and subtype-selective compounds such as (+)-30 and (+)-103, with high binding affinity (K-i = 0.2 nM) for alpha(1a) receptor and greater than 1500-fold selectivity over alpha(1b) and alpha(1d) adrenoceptors. The compounds were found to be functional antagonists in human, rat, and dog prostate tissues. Compound (+)-103 exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (K-b(DBP)/K-b(IUP) = 40) suggesting uroselectivity for alpha(1a)-selective compounds.
引用
收藏
页码:4764 / 4777
页数:14
相关论文
共 38 条
[21]   Pharmacological options in the treatment of benign prostatic hyperplasia [J].
Kenny, B ;
Ballard, S ;
Blagg, J ;
Fox, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (09) :1293-1315
[22]   EFFECT OF ALPHA(1)-ADRENOCEPTOR ANTAGONISTS ON PROSTATIC PRESSURE AND BLOOD-PRESSURE IN THE ANESTHETIZED DOG [J].
KENNY, BA ;
NAYLOR, AM ;
CARTER, AJ ;
READ, AM ;
GREENGRASS, PM ;
WYLLIE, MG .
UROLOGY, 1994, 44 (01) :52-57
[23]  
KIRBY RS, 1993, BENIGN PROSTATIC HYP
[24]  
KNEPPER SM, 1995, J PHARMACOL EXP THER, V274, P97
[25]  
LAZ TM, 1994, MOL PHARMACOL, V46, P414
[26]  
LEPOR H, 1990, PROSTATE, P75
[27]   LONG-TERM EFFICACY AND SAFETY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA [J].
LEPOR, H .
UROLOGY, 1995, 45 (03) :406-413
[28]   Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e]isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione (A-131701): A uroselective alpha(1A) adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia [J].
Meyer, MD ;
Altenbach, RJ ;
Basha, FZ ;
Carroll, WA ;
Drizin, I ;
Elmore, SW ;
Ehrlich, PP ;
Lebold, SA ;
Tietje, K ;
Sippy, KB ;
Wendt, MD ;
Plata, DJ ;
Plagge, F ;
Buckner, SA ;
Brune, ME ;
Hancock, AA ;
Kerwin, JF .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (20) :3141-3143
[29]  
MONDA JM, 1994, INFECT UROL, P47
[30]   KMD-3213, a novel alpha(1A)-adrenoceptor antagonist, potently inhibits the functional alpha(1)-adrenoceptor in human prostate [J].
Moriyama, N ;
Akiyama, K ;
Murata, S ;
Taniguchi, J ;
Ishida, N ;
Yamazaki, S ;
Kawabe, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 331 (01) :39-42